Wenger Vieli acted as Swiss legal advisor to NLS Pharmaceutics on all Swiss legal matters in connection with the direct offering and concurrent private placement transaction with certain investors to issue 806,452 of common shares and 806,452
Tags :NLS Pharmaceutics
NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company, has entered into a definitive agreement with BVF PARTNERS to raise aggregate gross proceeds of up to USD 30.0 million in a two-tranche private placement. The net proceeds will
Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m. NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
